Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Us

Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users An analysis of the Food and Drug Administration's Adverse Event Reporting System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported among users of Reglan or its generic version, metoclopramide. Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements of the extremities, including lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations